Product Description
(Sourced from: https://www.benzinga.com/pressreleases/26/10/g62650229/proqr-present-clinical-and-preclinical-progress-ax-0810-and-ax-0811-upcoming-conferences)
Mechanisms of Action: NTCP Inhibitor
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: N/A
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: ProQR
Company Location: Europe
Company Founding Year: 2012
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium
Active Clinical Trial Count: 1
Recent & Upcoming Milestones
- Clinical Outcomes Expected - ProQR announced they will present P0 Biliary Atresia|Bile Duct Diseases results in 4Q26 for AX-0811
- Clinical Outcomes Expected - ProQR announced they will present P1 Healthy Volunteers results in 1Q27 for AX-0811
- Clinical Outcomes Expected - ProQR announced they will present P2 Biliary Atresia results in 3Q28 for AX-0811
Highest Development Phases
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
2026-526764-21-00 |
PQ-0811-101 | P1 |
Not yet recruiting |
Healthy Volunteers |
2027-04-29 |
Recent News Events
Date |
Type |
Title |
|---|
